Effect of Febuxostat versus Allopurinol on the Glomerular Filtration Rate and Hyperuricemia in Patients with Chronic...

Area of Science:

• Nephrology
• Pharmacology
• Internal Medicine

Background:

• Hyperuricemia is a known risk factor for chronic kidney disease (CKD) progression.
• Managing elevated serum uric acid (SUA) levels is crucial for patients with CKD stages 3-4.

Purpose of the Study:

• To compare the efficacy of febuxostat and allopurinol in managing hyperuricemia.
• To evaluate the impact of febuxostat versus allopurinol on the progression of chronic kidney disease.

Main Methods:

• A comparative study involving 101 patients with Stage 3-4 CKD and hyperuricemia (>7 mg/dL).
• Patients received either febuxostat or allopurinol for at least 6 months.
• Key metrics included serum uric acid (SUA), serum creatinine, and estimated glomerular filtration rate (eGFR) at baseline and 6 months.

Main Results:

• Febuxostat demonstrated a significantly greater reduction in SUA (3.9 ± 1.7 mg/dL) compared to allopurinol (2.1 ± 1.0 mg/dL) (P = 0.004).
• The median rate of eGFR decline was 1.2 mL/min/1.73 m2 with febuxostat versus 3.1 mL/min/1.73 m2 with allopurinol, a difference that was not statistically significant (P = 0.136).
• No serious adverse events were reported for either treatment group.

Conclusions:

• Febuxostat is more effective than allopurinol in reducing serum uric acid levels in patients with Stage 3-4 CKD.
• Current data do not show a significant difference in CKD progression between febuxostat and allopurinol over a 6-month period.
• Larger randomized trials with longer follow-up are needed to ascertain the long-term effects of febuxostat on CKD progression.